Arthur Sands

9.5k citations

62 papers · 6.5k indexed · 2 hit papers · h-index 35

Impact in

Oncology top 1%
- Cancer-related Molecular Pathways
Endocrinology, Diabetes and Metabolism top 1%
- Diabetes Treatment and Management

Papers in

Endocrinology, Diabetes and Metabolism 18
- Diabetes Treatment and Management 11
- Diabetes Management and Research 6
Oncology 18
- Cancer-related Molecular Pathways 10
- CAR-T cell therapy research 6

Co-authors: Brian Zambrowicz Allan Bradley Gregor Eichele Dae‐Sik Lim Paul Hasty Susan B. Parker Alan Rawls J. Wade Harper
Journals: Nature (3 papers)Veterinary Pathology (3 papers)Clinical Therapeutics (3 papers)Proceedings of the National Academy of Sciences (3 papers)Gastroenterology (3 papers)
Partner nations: United States Germany Netherlands

In The Last Decade

Arthur Sands

62 papers receiving 6.4k citations

Hit Papers

align trajectories log scale

Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 1997 · 848 citations

Peers

Countries citing papers authored by Arthur Sands

Since Specialization

Citations

This map shows the geographic impact of Arthur Sands's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur Sands with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur Sands more than expected).

Fields of papers citing papers by Arthur Sands

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur Sands. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur Sands. The network helps show where Arthur Sands may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Arthur Sands, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Arthur Sands Line = papers co-authored together Arthur Sands links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	High-Throughput Screening of Mouse Gene Knockouts Identifies Established and Novel High Body Fat Phenotypes Diabetes Metabolic Syndrome and Obesity ·D.R. Powell, Jean‐Pierre Revelli, Deon Doree, Christopher M. DaCosta, Urvi Desai, Melanie K. Shadoan, Carla Pamela Ruiz Coronel, Michael A. Mullens, Valenzuela-Godoy Fabian, Zhi‐Ming Ding, Laura Kirkpatrick, Peter Vogel, Brian Zambrowicz, Arthur Sands, Kenneth A. Platt, Gwenn M. Hansen, Robert Brommage	2021	9
2	98 NX-0255, a small molecule CBL-B inhibitor, expands and enhances tumor infiltrating lymphocytes (TIL) for use in adoptive cancer immunotherapy Regular and Young Investigator Award Abstracts ·Sarah Whelan, Jennifa Gosling, Eyad El Sarraj, Frederick Cohen, 曾麗虹, Janine Powers, Gwenn M. Hansen, Michael T. Lotze, Arthur Sands	2021	4
3	Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial Pancreas ·Matthew H. Kulke, Dieter Hoersch, Martyn Caplin, Lowell Anthony, Emily K. Bergsland, Kjell Öberg, Staffan Welin, Richard R.P. Warner, Catherine Lombard‐Bohas, Pamela L. Kunz, Enrique Grande, Juan W. Valle, Douglas Fleming, Pablo Lapuerta, Phillip Banks, Shanna Jackson, Vedovato Júnior, Odair, 1977-, Brian Zambrowicz, Arthur Sands, Marianne Pavel	2016	1
4	LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion Clinical Therapeutics ·Brian Zambrowicz, Pablo Lapuerta, Paul Strumph, Phillip Banks, Alan Wilson, Ike Ogbaa, Arthur Sands, David R. Powell	2014	34
5	Egg consumption and risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort studies BMJ ·Rong Ying, Lijun Chen, Tao Zhu, Yadong Song, Yu Ma, Zhilei Shan, Arthur Sands, Fang Hu, Lu Liu	2013	261
6	Study Design and Rationale of a Dose‐Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy Clinical Cardiology ·Pablo Lapuerta, Julio Rosenstock, Brian Zambrowicz, David R. Powell, Ike Ogbaa, Joel Freiman, William T. Cefalu, Phillip Banks, Kenny Frazier, A. Rameshbabu, Arthur Sands	2013	12
7	LX4211 Increases Serum Glucagon-Like Peptide 1 and Peptide YY Levels by Reducing Sodium/Glucose Cotransporter 1 (SGLT1)–Mediated Absorption of Intestinal Glucose Journal of Pharmacology and Experimental Therapeutics ·David R. Powell, Melinda Smith, Jennifer Greer, Angela L. Harris, Sharon Zhao, Christopher M. DaCosta, Faika Mseeh, Melanie K. Shadoan, Arthur Sands, Brian Zambrowicz, Zhi‐Ming Ding	2013	156
8	Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes Clinical Therapeutics ·Brian Zambrowicz, Zhi‐Ming Ding, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Melinda Smith, Dennis Ruff, Arthur Sands, David R. Powell	2013	65
9	Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects Clinical Therapeutics ·Brian Zambrowicz, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Kristi A. Boehm, Dennis Ruff, David R. Powell, Arthur Sands	2013	52
10	LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial Clinical Pharmacology & Therapeutics ·Brian Zambrowicz, J Freiman, Phil Brown, Kenny Frazier, Anne Turnage, S Tóth, Qiang Liu, Melanie K. Shadoan, Phillip Banks, Faika Mseeh, David B. Rawlins, Nicole C. Goodwin, Ross Mabon, Bryce A. Harrison, Alan Wilson, Arthur Sands, David R. Powell	2012	202
11	Large-scale gene trapping in C57BL/6N mouse embryonic stem cells Genome Research ·Gwenn M. Hansen, Diane C. Markesich, Jone Narbaiza, Jason Osei Konadu, Mikel Martínez Iglesia, 黄海兴, Richard H. Finnell, Arthur Sands, Brian Zambrowicz, Alejandro Abuin	2008	100
12	Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice Proceedings of the National Academy of Sciences ·Urvi Desai, Zeng Feng Li, Kyu Hyuck Chung, Cuihua Gao, Jason Gay, Thomas Heawood, Gwenn M. Hansen, GIzem Yücel, Kenneth A. Platt, Arthur Sands, Matthias Schneider, Isaac Van Sligtenhorst, Adisak Suwanichkul, Peter Vogel, Gunale AV, Bogustaw Broda, Brian Zambrowicz, Greg Landes, D.R. Powell	2007	155
13	Suitability of human juvenile pancreatic islets for clinical use Diabetologia ·Appakalai N. Balamurugan, Ying Chang, Suzanne Bertera, Arthur Sands, V. Shankar, Massimo Trucco, Rita Bottino	2006	47
14	Absence of p21 partially rescues Mdm4 loss and uncovers an antiproliferative effect of Mdm4 on cell growth Oncogene ·Heather A. Steinman, Hayla K. Sluss, Arthur Sands, Germán Pihán, Stephen N. Jones	2004	32
15	Full-speed mammalian genetics: in vivo target validation in the drug discovery process Trends in biotechnology ·Alejandro Abuin, Kathleen H. Holt, Kenneth A. Platt, Arthur Sands, Brian Zambrowicz	2002	32
16	Disruption of Ini1 Leads to Peri-Implantation Lethality and Tumorigenesis in Mice Molecular and Cellular Biology ·Cynthia J. Guidi, Arthur Sands, Brian Zambrowicz, 白鳥昂太郎, Delia Demers, William Webster, Thomas W. Smith, Anthony N. Imbalzano, Stephen N. Jones	2001	241
17	Persistence of p53 mutations and resistance of keratinocytes to apoptosis are associated with the increased susceptibility of mice lacking the XPC gene to UV carcinogenesis Oncogene ·Honnavara N. Ananthaswamy, Allal Ouhtit, Randall Evans, Geoff Barker, 幸太郞藤野, Arthur Sands, Claudio J. Conti	1999	25
18	Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells Nature ·Brian Zambrowicz, Glenn A. Friedrich, Eric C. Buxton, Stan L. Lilleberg, Christophe Person, Arthur Sands	1998	372
19	Defective Global Genome Repair in XPC Mice Is Associated with Skin Cancer Susceptibility But Not with Sensitivity to UVB Induced Erythema and Edema Journal of Investigative Dermatology ·Rob J. W. Berg, Hendrik J.T. Ruven, Arthur Sands, Frank R. de Gruijl, Leon H.F. Mullenders	1998	74
20	Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 Nature ·Shyam K. Sharan, Masami Morimatsu, Urs Albrecht, Dae‐Sik Lim, Qiu Ru-hui, Christopher Dinh, Arthur Sands, Gregor Eichele, Paul Hasty, Allan Bradley Hit paper breakdown →	1997	848

About Arthur Sands

Arthur Sands is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology, Aging, Gastroenterology and Molecular Biology, having authored 62 papers that have together received 6.5k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (11 papers), Cancer-related Molecular Pathways (10 papers), Pancreatic function and diabetes (9 papers), CRISPR and Genetic Engineering (7 papers), Diabetes Management and Research (6 papers), Neuroendocrine Tumor Research Advances (6 papers), CAR-T cell therapy research (6 papers) and Neuroblastoma Research and Treatments (6 papers). The work is most often cited by research in Oncology (2.1k citations), Endocrinology, Diabetes and Metabolism (1.1k citations), Molecular Biology (4.0k citations), Cancer Research (672 citations) and Genetics (1.1k citations). Arthur Sands has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Brian Zambrowicz, Allan Bradley, Gregor Eichele, Dae‐Sik Lim, Paul Hasty, Susan B. Parker, Alan Rawls, J. Wade Harper, Stephen J. Elledge and Eric N. Olson. Their work appears in journals such as Nature, Veterinary Pathology, Clinical Therapeutics, Proceedings of the National Academy of Sciences and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact